Today, President Donald Trump announced the “Largest Development to Date in Bringing Most-Favored-Nation (MFN) Pricing to American Patients via the White House website and an Oval Office press conference. The new agreements announced this afternoon include nine major pharmaceutical manufacturers, including Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi, and will help “reduce prices on drugs that treat numerous costly and chronic conditions, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, COPD, hepatitis B and C, HIV, and certain cancers,” according to the White House Fact Sheet. The agreements will provide “every State Medicaid program in the country [with] access to MFN drug prices on products made by the nine companies” which will result in “billions of…
Click here to read the full article at The Gateway Pundit.
